- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07850284
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
This study evaluates whether daily SMS-based (text messages) symptom monitoring is feasible and acceptable in patients who are undergoing treatment for multiple myeloma (MM) or systemic light chain amyloidosis (AL), and whether it can help in early identification of symptoms that may require clinical attention.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Clinical Trials Referral Office
- Telefoonnummer: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
Studie Contact Back-up
- Naam: Sarah Aug
- Telefoonnummer: 507-538-1307
Studie Locaties
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Mayo Clinic in Rochester
-
Contact:
- Sarah Aug
- Telefoonnummer: 507-538-1301
-
Hoofdonderzoeker:
- Nadine Abdallah, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Patients age ≥ 18 years who have a diagnosis of MM and/or AL amyloidosis and are planned to start treatment at Mayo Clinic or another treatment facility
Beschrijving
Inclusion Criteria:
- Age >= 18 years
- Diagnosis of MM or AL based on IMWG diagnostic criteria
- Planned to start a new treatment within 14 days (+/-7 days)
- Able to provide written informed consent
Exclusion Criteria:
- Not able to give informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Observational
Patients are enrolled in the Quality of life text message system and receive SMS text messages and complete questionnaires daily for 3 months on study. |
Non-interventional study
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Engagement (Aim 1) - daily and weekly response rates
Tijdsspanne: Up to 3 months
|
Engagement will be evaluated by daily and weekly response rates. A response rate of ≥60% to daily prompts (e.g., ≥4 days per week) will be considered acceptable engagement. |
Up to 3 months
|
|
Engagement (Aim 1) - uninterrupted participation
Tijdsspanne: Up to 3 months
|
Engagement will be evaluated by the duration (number of days) of uninterrupted participation (e.g., consecutive response to daily prompts with missed days). |
Up to 3 months
|
|
Engagement (Aim 1) - complete symptom data
Tijdsspanne: Up to 3 months
|
Engagement will be evaluated by the proportion of days with complete symptom data entered by participants. |
Up to 3 months
|
|
Acceptability (Aim 1) - CSQ-8
Tijdsspanne: Up to 3 months
|
Acceptability will be measured using a post study survey: Client Satisfaction Questionnaire-8 (CSQ-8). The CSQ-8 is a self-report questionnaire used to measure general client satisfaction. It consists of 8 questions answered on a 4-point scale (e.g., quite dissatisfied, mildly dissatisfied, mostly satisfied, very satisfied). Total scores range from 8 to 32 with higher scores indicating higher satisfaction. |
Up to 3 months
|
|
System-generated alerts (Aim 2)
Tijdsspanne: Up to 3 months
|
Will determine the proportion of alerts that prompt documented clinical actions (e.g., triage calls, provider outreach, medication adjustments, referrals, and/or unplanned visits). Alerts will be considered effective if ≥30% of alerts prompt clinical actions. |
Up to 3 months
|
|
Symptom and Quality of Life (QOL) trajectories (Aim 3) - PROMIS-29
Tijdsspanne: Baseline to 3 months
|
Daily symptom and quality of life (QOL) trajectories will be modeled across treatment cycles. The Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) is used to assess patient-reported outcomes over the past 7 days across seven health domains: physical function, anxiety, depression, fatigue, sleep disturbance, social roles participation, and pain interference. Scores are scaled so that an average person would have a score of 50. Higher scores indicate more of the item being measured. Raw scores are converted to T-scores, with higher scores indicating better quality of life (QOL). Changes in PROMIS-29 scores will be evaluated using established minimal clinically important differences (MCIDs). Clinically meaningful deterioration will be defined as ≥ 2-point worsening in symptom severity, emergence of new severe symptoms, and deterioration in QOL scores in ≥20% of patients. |
Baseline to 3 months
|
|
Symptom and QOL trajectories (Aim 3) - SF-36
Tijdsspanne: Baseline to 3 months
|
Daily symptom trajectories will be modeled across treatment cycles. The 36-Item Short Form Survey (SF-36) is used to measure patient health and disability. Participants rate items on a scale of 1 (all of the time) to 6 (none of the time) or 1 (not at all) to 5 (extremely) with higher scores indicating greater quality of life. Changes in SF-36 scores will be evaluated using established MCIDs. Clinically meaningful deterioration will be defined as ≥ 2-point worsening in symptom severity, emergence of new severe symptoms, and deterioration in QOL scores in ≥20% of patients. |
Baseline to 3 months
|
|
Change in Frailty status (Aim 4) - IMWG-FI
Tijdsspanne: Baseline to 3 months
|
Frailty will be assessed using the International Myeloma Working Group-Frailty Index (IMWG-FI). The IMWG-FI will be analyzed as a continuous and categorical variable; patients will be classified into 3 categories (fit, intermediate fit, or frail). Total scores range from 0-5, with a score of 0 indicating fit, a score of 1 indicating intermediate fitness, and a score of ≥2 indicating frailty. |
Baseline to 3 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Nadine H. Abdallah, MD, Mayo Clinic in Rochester
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Vaatziekten
- Hart-en vaatziekten
- Neoplasmata
- Metabole ziekten
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Hematologische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Neoplasmata, plasmacel
- Hemostatische aandoeningen
- Paraproteïnemieën
- Bloed eiwit stoornissen
- Hemorragische aandoeningen
- Proteostase-tekortkomingen
- Amyloïdose
- Voedings- en stofwisselingsziekten
- Hemische en lymfatische ziekten
- Immunoglobuline lichte keten amyloïdose
- Multipel myeloom
Andere studie-ID-nummers
- 26-002036
- NCI-2026-06651 (Register-ID: CTRP (Clinical Trial Reporting Program))
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .